Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox checked   Rule 13d-1(b)
Checkbox not checked   Rule 13d-1(c)
Checkbox not checked   Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person:  (1) The figures in Items 6, 8, 9, and 11 represent common stock, $0.001 par value per share ("Common Stock") of NextCure, Inc. (the "Issuer") held by Ikarian Healthcare Master Fund, L.P., a Cayman Islands exempted limited partnership (the "Fund"), and certain separately managed accounts. See Item 2 for more information. (2) The figure in Item 11 is based upon 5,079,305 shares of Common Stock of the Issuer outstanding, which includes the 500,282 shares of Common Stock of the Issuer that may be acquired by the Reporting Persons pursuant to warrants and the 4,579,023 shares of Common Stock of the Issuer outstanding as of November 9, 2026, as disclosed in the Issuer's quarterly report on Form 10-Q for the quarterly period ended September 30, 2026, filed with the U.S. Securities and Exchange Commission (the "SEC") on November 10, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person:  (1) The figures in Items 6, 8, 9, and 11 represent Common Stock of the Issuer held by the Fund and certain separately managed accounts. See Item 2 for more information. (2) The figure in Item 11 is based upon 5,079,305 shares of Common Stock of the Issuer outstanding, which includes the 500,282 shares of Common Stock of the Issuer that may be acquired by the Reporting Persons pursuant to warrants and the 4,579,023 shares of Common Stock of the Issuer outstanding as of November 9, 2026, as disclosed in the Issuer's quarterly report on Form 10-Q for the quarterly period ended September 30, 2026, filed with the SEC on November 10, 2026.


SCHEDULE 13G



 
Ikarian Capital, LLC
 
Signature:/s/ Neil Shahrestani
Name/Title:Neil Shahrestani, Sole Manager
Date:11/16/2026
 
Neil Shahrestani
 
Signature:/s/ Neil Shahrestani
Name/Title:Neil Shahrestani
Date:11/16/2026
Exhibit Information

A Joint Filing Agreement is incorporated herein by reference to Exhibit 99.1 to the Schedule 13G filed on December 15, 2025 by the Reporting Persons with the SEC.